## 3 Results
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline  & \multicolumn{2}{c}{**Genotype**} & \multicolumn{2}{c}{**\(p\)-Value**} & **Allele** & \multicolumn{2}{c}{\(p\)**-Value**} & **HWE \(p\)** \\ \hline rs10204525 \(PDCD1\) gene & GG & GA & AA & A & G & & \\ \hline \multirow{4}{*}{\begin{tabular}{c} Controls \\ (\(n\) = 43) \\ \end{tabular} } & Controls & 74.41 & 23.25 & 2.32 & & 13.95 & 86.05 & & 0.8362 \\ \cline{2-6}  & \begin{tabular}{c} Cases \\ (\(n\) = 43) \\ \end{tabular} & 81.39 & 16.27 & 2.32 & 0.717 & 10.47 & 89.53 & 0.486 & \\ \hline rs550675 \(COL9A1\) gene & CC & CT & TT & C & T & & \\ \hline \multirow{4}{*}{\
\begin{tabular}{c} Controls \\ (\(n\) = 43) \\ \end{tabular} } & Controls & 23.25 & 58.13 & 18.60 & & 52.33 & 47.67 & & 0.2784 \\ \cline{1-1} \cline{2-6}  &
\begin{tabular}{c} Cases \\ (\(n\) = 45) \\ \end{tabular} & 40 & 55.55 & 6.66 & 0.103 & 66.67 & 33.33 & 0.053 & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: The two variants investigated in the psoriasis group and control group. Statistical analyses were performed between mild and severe psoriasis according to PASI score (profile shown in Table 4), independent of clinical forms of psoriasis, but no statistically significant data were obtained. The Mann-Whitney and Kruskal-Wallis tests were used to compare the scores, and the frequency of alleles and genotypes was compared by applying the Chi-squared test. Frequencies results are presented in Table 5.  
The genotype frequency for rs550675 in _COL9A1_ gene was 40.0% (CC), 53.3% (CT) and 6.66% (TT) in psoriasis cases and 23.3% (CC), 58.1% (CT), 18.6% (TT) for controls. When comparing CC/TT genotypes between the psoriatic and healthy group, the TT genotype is associated with psoriasis (\(p\) = 0.039). The frequency of genotypes for rs10204525 in _PDCD1_ gene was 77.8% (GG), 15.6% (GA), 2.2% (AA), and 4.4% could not be determined in the patient group; and in the control group, the frequency was 74.4% (GG), 23.3% (GA), 2.3% (AA). Statistical analysis of these genotypes shows that rs10204525 was not associated with psoriasis susceptibility. These data are summarized in Table 6.  
Figure 1a,b show genotype percentage distribution of the two genes studied according to disease severity for each type of psoriasis. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Score** & **Type of psoriasis** & **N** & **Mean + SD** & **Median (Q1, Q2)** & \(p\)**-Value** \\ \hline \multirow{2}{*}{**PASI**} & mild & 18 & 6.33 \(\pm\) 1.97 & 20 (15, 24.5) & \multirow{2}{*}{\(<\)0.001} \\  & severe & 27 & 19.82 \(\pm\) 5.63 & 6 (5.25, 8) & \\ \multirow{2}{*}{**DLQI**} & mild & 18 & 9.50 \(\pm\) 5.51 & 12 (8, 18) & \\  & severe & 27 & 13.04 \(\pm\) 7.94 & 9 (5.25, 12) & \\ \hline \hline \end{tabular}
\end{table} 
Table 4: Descriptive statistics for PASI and DLQI scores. \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Statistics \({}^{\text{a}}\) Test** & **rs550675 (C/T)** & **rs10204525 (G/A)** \\ \hline Mann–Whitney U & 729.500 & 861.500 \\ \hline Wilcoxon W & 1675.500 & 1807.500 \\ \hline \(Z\) & \(-\)2.221 & \(-\)0.755 \\ \hline Asymp. Sig. (2-tailed) & \(p\) & 0.026 & 0.450 \\ \hline \hline \end{tabular} \({}^{\text{a}}\). Grouping variable: sample.  
\end{table} 
Table 3: Non-parametric Mann–Whitney test for investigated SNPs. \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Sporiasis Patients** & **Mild Sporiasis** & **Severe Sporiasis** & \(p\)**-Value** \\ \hline rs10204525 & \(n\) = 25 & \(n\) = 18 & \\ \hline GA & 11.11\% & 18.51\% & \\ \hline GG & 83.33\% & 74.07\% & \\ \hline AA & 5.55\% & 0.00\% & \\ \hline G & 88.88\% & 90.00\% & \\ \hline A & 11.11\% & 10.00\% & \\ \hline rs550675 & \(n\) = 27 & \(n\) = 18 & \\ \hline CT & 61.11\% & 48.14\% & \\ \hline CC & 27.77\% & 48.14\% & 0.309 \\ \hline TT & 11.11\% & 3.70\% & \\ \hline C & 58.33\% & 72.22\% & \\ \hline T & 41.66\% & 27.77\% & \\ \hline \hline \end{tabular}
\end{table} 
Table 5: _PDCD1_ and _COL9A1_ polymorphism in patients with mild or severe psoriasis.